Teva Pharmaceutical Industries (TEVA) Operating Leases (2018 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Operating Leases for 9 consecutive years, with $280.0 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Leases fell 2.78% year-over-year to $280.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $280.0 million (down 2.78% YoY) and the FY2025 annual result came in at $288.0 million, down 24.8% from the prior year.
• Operating Leases retreated to $280.0 million in Q1 2026 per TEVA's latest filing, from $288.0 million in the prior quarter.
• Over the last five years, Operating Leases for TEVA reached as high as $442.0 million in Q4 2022 and fell as low as $280.0 million in Q1 2026.
• A 5-year average of $333.6 million and a median of $324.0 million in 2023 frame the typical range for Operating Leases.
• The largest YoY upside for Operating Leases was 5.34% in 2025 against a maximum downside of 24.8% in 2025.
• Year by year, Operating Leases stood at $442.0 million in 2022, then decreased by 5.66% to $417.0 million in 2023, then decreased by 8.15% to $383.0 million in 2024, then dropped by 24.8% to $288.0 million in 2025, then retreated by 2.78% to $280.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $280.0 million, $288.0 million, and $283.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.